This Article Full Text Full Text (PDF) All Versions of this Article: 114/10/1063    most recent CIRCULATIONAHA.105.608869v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Price, J. F. Articles by Dreyer, W. J. Search for Related Content PubMed PubMed Citation Articles by Price, J. F. Articles by Dreyer, W. J. Related Collections Congestive Pediatric and congenital heart disease, including cardiovascular surgery

(Circulation. 2006;114:1063-1069.)
© 2006 American Heart Association, Inc.

Pediatric Cardiology

B-Type Natriuretic Peptide Predicts Adverse Cardiovascular Events in Pediatric Outpatients With Chronic Left Ventricular Systolic Dysfunction

Jack F. Price, MD; Anne K. Thomas, RN, MSN; Michelle Grenier, MD; Benjamin W. Eidem, MD; E. O’Brian Smith, PhD; Susan W. Denfield, MD; Jeffrey A. Towbin, MD; William J. Dreyer, MD

From the Department of Pediatrics, The Lillie Frank Abercrombie Section of Pediatric Cardiology, Baylor College of Medicine, Texas Children’s Hospital, Houston.

Correspondence to Jack F. Price, MD, Texas Children’s Hospital, 6621 Fannin, MC 19345C, Houston, TX 77030. E-mail jprice{at}bcm.tmc.edu

Received December 17, 2005; revision received July 7, 2006; accepted July 10, 2006.

Background— Plasma B-type natriuretic peptide (BNP) levels are elevated in adults with heart failure and correlate with functional classification and prognosis. The range and predictive power of BNP concentrations in children with chronic heart failure, however, are not known.

Methods and Results— Whole blood BNP concentrations were measured in 53 consecutive patients with chronic left ventricular (LV) systolic dysfunction (biventricular hearts, ejection fraction <50%, >3 months since diagnosis). Children who had been hospitalized within 3 months before potential enrollment and those <2 months or >21 years of age were excluded. BNP concentrations were measured with the Triage assay (Biosite Diagnostics, Inc, San Diego, Calif). Echocardiographers and clinicians were blinded to BNP levels. An adverse cardiovascular event was defined as cardiac death, cardiac-related hospitalization, or listing for cardiac transplantation. The median age of patients with LV dysfunction was 9.3 years (interquartile range [IQR], 2.7 to 15.1 years). BNP levels were elevated in children with LV dysfunction compared with healthy controls (median, 78 pg/mL [IQR, 22 to 551 pg/mL] versus median, 7 pg/mL [IQR, 5 to 11 pg/mL]; P<0.0001). Whole blood BNP concentrations were increased in patients who had a 90-day adverse cardiovascular event compared with those who did not (median, 735 pg/mL [IQR, 685 to 1510 pg/mL] versus median, 37 pg/mL [IQR, 14 to 92 pg/mL]; P<0.001). Patients with a BNP concentration 300 pg/mL were at increased risk of death, hospitalization, or listing for cardiac transplantation (adjusted hazard ratio, 63.6; P<0.0001).

Conclusions— BNP concentrations are elevated in children with chronic LV systolic dysfunction and predict the 90-day composite end point of death, hospitalization, or listing for cardiac transplantation.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				A. Bernus, B. D. Wagner, F. Accurso, A. Doran, H. Kaess, and D. D. Ivy Brain Natriuretic Peptide Levels in Managing Pediatric Patients With Pulmonary Arterial Hypertension Chest, March 1, 2009; 135(3): 745 - 751. [Abstract] [Full Text] [PDF]

				J. Mangat, C. Carter, G. Riley, Y. Foo, and M. Burch The clinical utility of brain natriuretic peptide in paediatric left ventricular failure Eur J Heart Fail, January 1, 2009; 11(1): 48 - 52. [Abstract] [Full Text] [PDF]

				O. Chikovani, J.-H. Hsu, R. Keller, T. R. Karl, A. Azakie, I. Adatia, P. Oishi, and J. R. Fineman B-type natriuretic peptide levels predict outcomes for children on extracorporeal life support after cardiac surgery. J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1179 - 1187. [Abstract] [Full Text] [PDF]

				J.-H. Hsu, R. L. Keller, O. Chikovani, H. Cheng, S. A. Hollander, T. R. Karl, A. Azakie, I. Adatia, P. Oishi, and J. R. Fineman B-type natriuretic peptide levels predict outcome after neonatal cardiac surgery. J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 939 - 945. [Abstract] [Full Text] [PDF]

				M. Fenton and M. Burch Understanding chronic heart failure Arch. Dis. Child., September 1, 2007; 92(9): 812 - 816. [Abstract] [Full Text] [PDF]